Crystal forms of immunomodulators
The invention relates to crystalline forms of a 3-substituted 1,2,4-oxadiazole compound, including an anhydrous crystalline form, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for pharmaceutical, veterinary, and agriculturally-relevant uses.
1. An anhydrous crystalline compound having the structure of formula (I),
and 2θ values of 10.2±0.2, 15.2±0.2, 15.8±0.2, 16.5±0.2, 17.6±0.2, 18.1±0.2, 18.8±0.2, 20.5±0.2, 21.8±0.2, 22.3±0.2, 22.9±0.2, 24.2±0.2, 25.4±0.2, 26.1±0.2, 26.4±0.2, 27.5±0.2, 28.1±0.2, 28.8±0.2, 29.3±0.2, 30.4±0.2, 30.6±0.2, 32.0±0.2, 33.4±0.2, 33.6±0.2, 34.6±0.2, 35.8±0.2, 36.7±0.2, 37.3±0.2, 38.2±0.2, 38.6±0.2, and 39.2±0.2.
2. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 90%.
3. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 91%.
4. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 92%.
5. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 93%.
6. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 94%.
7. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 95%.
8. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 96%.
9. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 97%.
10. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 98%.
11. The crystalline compound of claim 1 , wherein the purity of the crystalline compound is about 99%.
12. A pharmaceutical composition comprising the anhydrous crystalline compound of claim 1 and one or more pharmaceutically acceptable excipients.